sibutramine has been researched along with Somatoform Disorders in 1 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Somatoform Disorders: Disorders having the presence of physical symptoms that suggest a general medical condition but that are not fully explained by another medical condition, by the direct effects of a substance, or by another mental disorder. The MEDICALLY UNEXPLAINED SYMPTOMS must cause clinically significant distress or impairment in social, occupational, or other areas of functioning. In contrast to FACTITIOUS DISORDERS and MALINGERING, the physical symptoms are not under voluntary control. (APA, DSM-V)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Whisenhunt, BL | 1 |
| Williamson, DA | 1 |
| Netemeyer, RG | 1 |
| Andrews, C | 1 |
1 other study available for sibutramine and Somatoform Disorders
| Article | Year |
|---|---|
Health risks, past usage, and intention to use weight loss products in normal weight women with high and low body dysphoria.
Topics: Adolescent; Adult; Advertising; Analysis of Variance; Appetite Depressants; Body Image; Body Mass In | 2003 |